Whether you're just starting or fine-tuning your dose, you'll find everything you need to make informed decisions (and get the best results!)
two oral GLP-1 RA candidates expected to begin clinical trials imminently
At Vive Ageless Weight Loss Center, we leverage the power of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in your gastrointestinal tract, to help you achieve your weight loss and wellness goals
While Mounjaros clinical results are promising, differentiation versus Ozempic is not clean cut, as clinical results appear to be dose dependent, and Ozempic may have a slight advantage in terms of gastrointestinal (GI) tolerability and dropout rates (discontinuation rates due to adverse events in tirzepatide arms were 5.1% 7.9% compared to 3.8% in semaglutide cohort)
For women of childbearing potential, these medications are not recommended during pregnancy or breastfeeding, and discontinuation is advised at least 2 months before planned pregnancy for semaglutide and 1 month for tirzepatide